RE:RE:S.PI agree with you, and likely most longs -- who've been here since before covid test kit sales were part of DM's wheelhouse -- agree with you that AI is the real bread and butter of this company. For many, that was the main reason we bought in, after all. But it's a different world now.
Yes, the unexpected C-19 cash is a welcome boost, but it could be shortlived (probably not), making it difficult to factor in, for now anyway (there are still a lot of unknowns, at this point in time). Personally, I believe people are waking up to fact that Covid will continue to mutate, soon becoming vaccine-resistant, as recently stated by the CEO of Pfizer. It is here to stay, and therefore, testing is becoming an everyday part of everyday life like school and events, and doing business, in every industry that involves folks mingling with each other -- airlines, film making, whatever.
But back to AI; I think you're right, it's what's going to move us up in the nearterm; however, where I politely disagree is that test kit sales will continue to push the stock price down. This money should eventually be considered serious longterm income. If they win the $40M AI contract (multi year, co bid and although substantial money it's less income than the annual test kit sales), will be what secures Datametrex as a serious player on their original platform imho. I wouldn't be surprised to see the SP zoom to a 52 week high, if we get it. Not trying to pump, that's just my gut feeling or personal take on the situation because, again, I agree with you on the importance of AI income, at this time. Investors have been yearning for it, eager to see the big-money AI contracts start rolling in, so when they do, it will finally be showtime for patient longs, but let's not rule out the potential of Covid testing becoming an ongoing income that will eventually also drive up the stock price.